Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0001453687-24-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-03-20 | 2024-03-18 | RNAC | SPRINGER TIMOTHY A | Dir, 10% | P - Purchase | $0.6 | +19.0K | 31.07M | +0.1% | +$11.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-18 | P | A | 19,044 | $0.6 | 31,073,406 | I See Footnote | — | — | (F1) The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.575 to $0.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. |